Aix-Cel

A solid strategy and great execution have led BTIG analyst, Dane Leone, to upgrade his recommendation on Kite Pharma Inc. (NASDAQ: KITE) to Buy, and set a price target of $100. The Core Theses That Sees Upside Over 20% Kita Pharma’s trademark brand, Aix-Cel, should garner approximately 60...